301 related articles for article (PubMed ID: 38555465)
1. Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors.
Liao B; Wang J; Yuan Y; Luo H; Ouyang X
Cancer Cell Int; 2024 Mar; 24(1):122. PubMed ID: 38555465
[TBL] [Abstract][Full Text] [Related]
2. The Pivotal Function of SLC16A1 and SLC16A1-AS1 in Cancer Progress: Molecular Pathogenesis and Prognosis.
Zhou Y; Tan F; Wang Z; Zhou G; Yuan C
Mini Rev Med Chem; 2024 Apr; ():. PubMed ID: 38616756
[TBL] [Abstract][Full Text] [Related]
3. A pan-cancer analysis indicates long noncoding RNA HAND2-AS1 as a potential prognostic, immunomodulatory and therapeutic biomarker in various cancers including colorectal adenocarcinoma.
Samadi P; Shahnazari M; Shekari A; Maghool F; Jalali A
Cancer Cell Int; 2023 Dec; 23(1):307. PubMed ID: 38042769
[TBL] [Abstract][Full Text] [Related]
4. lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer.
Liu HY; Lu SR; Guo ZH; Zhang ZS; Ye X; Du Q; Li H; Wu Q; Yu B; Zhai Q; Liu JL
J Investig Med; 2020 Jan; 68(1):52-59. PubMed ID: 31371390
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA SLC16A1-AS1: its multiple tumorigenesis features and regulatory role in cell cycle in oral squamous cell carcinoma.
Feng H; Zhang X; Lai W; Wang J
Cell Cycle; 2020 Jul; 19(13):1641-1653. PubMed ID: 32450050
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of lncRNA SLC16A1-AS1 Suppresses the Growth and Metastasis of Breast Cancer
Jiang B; Xia J; Zhou X
Front Oncol; 2022; 12():712475. PubMed ID: 35372039
[TBL] [Abstract][Full Text] [Related]
7. LncRNA SLC16A1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-411/MITD1 axis.
Duan C
J Clin Lab Anal; 2022 Apr; 36(4):e24344. PubMed ID: 35293026
[TBL] [Abstract][Full Text] [Related]
8. Silencing lncRNA SLC16A1-AS1 Induced Ferroptosis in Renal Cell Carcinoma Through miR-143-3p/SLC7A11 Signaling.
Li YZ; Zhu HC; Du Y; Zhao HC; Wang L
Technol Cancer Res Treat; 2022; 21():15330338221077803. PubMed ID: 35167383
[No Abstract] [Full Text] [Related]
9. SLC16A1-AS1 enhances radiosensitivity and represses cell proliferation and invasion by regulating the miR-301b-3p/CHD5 axis in hepatocellular carcinoma.
Pei S; Chen Z; Tan H; Fan L; Zhang B; Zhao C
Environ Sci Pollut Res Int; 2020 Dec; 27(34):42778-42790. PubMed ID: 32748357
[TBL] [Abstract][Full Text] [Related]
10. Deciphering the oncogenic landscape: Unveiling the molecular machinery and clinical significance of LncRNA TMPO-AS1 in human cancers.
Saraswat SK; Mahmood BS; Ajila F; Kareem DS; Alwan M; Athab ZH; Shaier JB; Hosseinifard SR
Pathol Res Pract; 2024 Mar; 255():155190. PubMed ID: 38330619
[TBL] [Abstract][Full Text] [Related]
11. LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival.
Tian J; Hu D
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101490. PubMed ID: 33744723
[TBL] [Abstract][Full Text] [Related]
12. MiR-526b targets lncRNA SLC16A1-AS1 to suppress cell proliferation in triple-negative breast cancer.
Zhao X; Fu L; Zhai L; Yang X; Gao R
J Biochem Mol Toxicol; 2023 Mar; 37(3):e23247. PubMed ID: 36654514
[TBL] [Abstract][Full Text] [Related]
13. LncRNA SLC16A1-AS1 is Upregulated in Glioblastoma and Promotes Cancer Cell Proliferation by Regulating miR-149 Methylation.
Long Y; Li H; Jin Z; Zhang X
Cancer Manag Res; 2021; 13():1215-1223. PubMed ID: 33603467
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-1269 is downregulated in glioblastoma and its maturation is regulated by long non-coding RNA SLC16A1 Antisense RNA 1.
Jin Z; Li H; Long Y; Liu R; Ni X
Bioengineered; 2022 May; 13(5):12749-12759. PubMed ID: 35609320
[TBL] [Abstract][Full Text] [Related]
15. LncRNA SLC16A1-AS1 Suppresses Cell Proliferation in Cervical Squamous Cell Carcinoma (CSCC) Through the miR-194/SOCS2 Axis.
Zhang H; Jin S; Ji A; Ma Y; Zhang C; Wang A; Wang R
Cancer Manag Res; 2021; 13():1299-1306. PubMed ID: 33603475
[TBL] [Abstract][Full Text] [Related]
16. LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1.
Logotheti S; Marquardt S; Gupta SK; Richter C; Edelhäuser BAH; Engelmann D; Brenmoehl J; Söhnchen C; Murr N; Alpers M; Singh KP; Wolkenhauer O; Heckl D; Spitschak A; Pützer BM
Theranostics; 2020; 10(21):9620-9643. PubMed ID: 32863950
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the subcellular location of lncRNA SLC16A1-AS1 and its interaction with premature miR-5088-5p in oral squamous cell carcinoma.
Li T; Wang D; Yang S
Odontology; 2023 Jan; 111(1):41-48. PubMed ID: 35829849
[TBL] [Abstract][Full Text] [Related]
18. LncRNA SLC16A1-AS1 regulates the miR-182/PDCD4 axis and inhibits the triple-negative breast cancer cell cycle.
Jiang B; Liu Q; Gai J; Guan J; Li Q
Immunopharmacol Immunotoxicol; 2022 Aug; 44(4):534-540. PubMed ID: 35316129
[TBL] [Abstract][Full Text] [Related]
19. The role of long non-coding RNA AFAP1-AS1 in human malignant tumors.
Ji D; Zhong X; Jiang X; Leng K; Xu Y; Li Z; Huang L; Li J; Cui Y
Pathol Res Pract; 2018 Oct; 214(10):1524-1531. PubMed ID: 30173945
[TBL] [Abstract][Full Text] [Related]
20. A review on the role of gamma-butyrobetaine hydroxylase 1 antisense RNA 1 in the carcinogenesis and tumor progression.
Hu J; Liu J; Zhou S; Luo H
Cancer Cell Int; 2023 Nov; 23(1):263. PubMed ID: 37925403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
